肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析

doi:10.11904/j.issn.1002-3070.2022.03.004

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (3): 214-219.doi: 10.11904/j.issn.1002-3070.2022.03.004

肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析

张浩¹, 杨新官², 何涌¹

1.桂林医学院第二附属医院放射科(桂林 541000);
2.桂林市人民医院放射科

收稿日期:2021-12-10 修回日期:2022-05-10 出版日期:2022-06-28 发布日期:2022-06-28
通讯作者: 何涌,E-mail:glyi2007@qq.com
作者简介:张浩,男,(1994-),硕士研究生,从事肿瘤影像学方面的研究。
基金资助:
广西自然科学基金项目(编号:2018GXNSFAA281080)

Analysis of the correlation between sarcopenia and the clinicopathological characteristics and prognosis of advanced NSCLC

ZHANG Hao¹, YANG Xinguan², HE Yong¹

1. Department of Radiation Oncolocy,The Second Affiliated Hospital of Guilin Medical University,Guilin 541000,China;
2. Department of Radiation Oncolocy,Guilin People′s Hospital

Received:2021-12-10 Revised:2022-05-10 Online:2022-06-28 Published:2022-06-28

摘要/Abstract

摘要： 目的研究合并肌少症的晚期非小细胞肺癌患者的临床病理特征,评估肌少症对晚期非小细胞肺癌患者无进展生存期(PFS)和总生存期(OS)的影响。方法选择2017年6月—2019年12月期间我院收治的112例Ⅲb期~Ⅳ期非小细胞肺癌患者,根据骨骼肌指数(SMI)将患者分为合并肌少症组(64例)和未合并肌少症组(48例)。所有患者采用电话或门诊随访,比较两组患者的PFS及OS;采用Cox回归分析晚期非小细胞肺癌预后危险因素。结果合并肌少症组的PFS、OS均低于未合并肌少症组(P＜0.05)。多因素Cox风险比例回归分析显示肌少症、T分期是晚期非小细胞肺癌患者PFS的独立影响因素(P＜0.05),肌少症、淋巴结转移是影响晚期非小细胞肺癌患者OS的独立危险因素(P＜0.05)。结论治疗前合并肌少症的晚期非小细胞肺癌患者PFS及OS均低于未合并肌少症者,治疗前合并肌少症可能作为晚期非小细胞肺癌患者预后评估的指标。

关键词: 肌少症, 晚期非小细胞肺癌, 病理特征, 危险因素, 预后

Abstract: Objective The objective of this study was to determine the clinicopathological characteristics of advanced non-small cell lung cancer patients with sarcopenia,and to evaluate the effect of sarcopenia on progression-free survival(PFS)and overall survival(OS)in advanced non-small cell lung cancer patients. Methods A total of 112 patients with stage IIIb-IV non-small cell lung cancer who were treated in our hospital from June 2017 to December 2019 were selected,and the patients were divided into the sarcopenia group(64 cases)and the non-sarcopenia group(48 cases).All patients were followed up by telephone or outpatient service.PFS and OS between the two groups were compared.Cox regression was used to analyze the prognostic risk factors of advanced non-small cell lung cancer. Results The survival rates of PFS and OS in the group with sarcopenia were lower than those in the group without sarcopenia(P＜0.05).Multivariate Cox hazard proportional regression analysis showed that sarcopenia and T stage were independent risk factors for PFS in patients with advanced non-small cell lung cancer(P＜0.05);sarcopenia and lymph node metastasis were independent risk factors for OS in patients with advanced non-small cell lung cancer(P＜0.05). Conclusion The PFS and OS of advanced non-small cell lung cancer patients with sarcopenia are lower than those of non-sarcopenic patients,sarcopenia may be used as a prognostic indicator for advanced non-small cell lung cancer patients.

Key words: Sarcopenia, Advanced non-small cell lung cancer, Pathological features, Risk factors, Prognosis

中图分类号:

R734.2

张浩, 杨新官, 何涌. 肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(3): 214-219.

ZHANG Hao, YANG Xinguan, HE Yong. Analysis of the correlation between sarcopenia and the clinicopathological characteristics and prognosis of advanced NSCLC[J]. Journal of Practical Oncology, 2022, 36(3): 214-219.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.03.004

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I3/214

参考文献

1 赫捷,李霓,陈万青,等.中国肺癌筛查与早诊早治指南(2021,北京)[J].中华肿瘤杂志,2021,43(3):243-268.
2 宁晔,谢冬,佘云浪,等.2020版NCCN肺癌筛查指南解读[J].中国胸心血管外科临床杂志,2020,27(3):251-254.
3 董晓平,张雪,郭冬利,等.肺鳞状细胞癌预后相关影响因素研究进展[J].实用肿瘤学杂志,2021,35(4):380-385.
4 方志红,李天苗,许荣忠,等.246例非小细胞肺癌的预后影响因素分析[J].现代肿瘤医学,2017,25(8):1234-1236.
5 Marasco G,Serenari M,Renzulli M,et al.Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments[J].J Gastroenterol,2020,55(10):927-943.
6 Schaffler-Schaden D,Mittermair C,Birsak T,et al.Skeletal muscle index is an independent predictor of early recurrence in non-obese colon cancer patients[J].Langenbecks Arch Surg,2020,405(4):469-477.
7 Fearon K,Strasser F,Anker SD,et al.Definition and classification of cancer cachexia:an international consensus[J].Lancet Oncol,2011,12(5):489-495.
8 刘娟,丁清清,周白瑜,等.中国老年人肌少症诊疗专家共识(2021)[J].中华老年医学杂志,2021,40(8):943-952.
9 Cawthon PM.Recent progress in sarcopenia research:a focus on operationalizing a definition of sarcopenia[J].Curr Osteoporos Rep,2018,16(6):730-737.
10 李周华,季爽,胡先纬,等.肺癌患者并发肌肉减少症的危险因素分析及其与临床预后的相关性探讨[J].中国全科医学,2021,24(26):3310-3315.
11 Suzuki Y,Okamoto T,Fujishita T,et al.Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer[J].Lung Cancer,2016,101:92-97.
12 Rossi S,Di Noia V,Tonetti L,et al.Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?[J].Future Oncol,2018,14(10):919-926.
13 Shiroyama T,Nagatomo I,Koyama S,et al.Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors:a preliminary retrospective study[J].Sci Rep,2019,9(1):2447.
14 任姗姗,李冠臻,汪明芳,等.高龄老年人肌少症与膳食摄入的相关性研究[J].中华老年医学杂志,2021,40(2):212-215.
15 Beaudart C,Dawson A,Shaw SC,et al.Nutrition and physical activity in the prevention and treatment of sarcopenia:systematic review[J].Osteoporos Int,2017,28(6):1817-1833.
16 Cereda E,Turri A,Klersy C,et al.Whey protein isolate supplementation improves body composition,muscle strength,and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy[J].Cancer Med,2019,8(16):6923-6932.
17 唐微,闫翔,范萍,等.膳食营养干预联合抗阻力训练治疗老年男性肌少症患者的临床效果分析[J].现代生物医学进展,2020,20(14):2698-2701.
18 樊菡,王莉,李潇.不同分期老年肌少症患者睾酮、雌二醇、IL-6水平的相关性[J].中华骨质疏松和骨矿盐疾病杂志,2021,14(1):35-40.

[1]	王洪英, 李岩, 韩鑫浩, 魏孝礼, 贾慧珣, 袁文娟, 张秋菊. 基于免疫相关lncRNAs的胃癌早期诊断和预后风险模型的构建和验证[J]. 实用肿瘤学杂志, 2022, 36(2): 119-126.
[2]	尹翼, 欧朝阳, 何爱琴. GAB2在卵巢癌组织中的表达及其与预后的相关性[J]. 实用肿瘤学杂志, 2022, 36(2): 150-155.
[3]	李伟华, 张广凤, 马骊骊, 何品, 王雯, 李顶夫. 基于TCGA数据库代谢相关基因构建乳腺癌预后模型[J]. 实用肿瘤学杂志, 2022, 36(1): 37-43.
[4]	王榆平, 思美丽, 孙小霞, 郭玉琳. HPIP在子宫内膜癌中高表达及其在生存预后分析中的意义[J]. 实用肿瘤学杂志, 2022, 36(1): 44-48.
[5]	曹世玉, 姜永冬. 基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响[J]. 实用肿瘤学杂志, 2022, 36(1): 89-93.
[6]	王丽娜, 王乐, 靳红, 李奇, 成海燕. UBQLN1在宫颈癌中的表达及其对预后的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 506-510.
[7]	陈奕心, 孙轶华, 程洋洋, 何凯桐, 郭婷. 术前炎症相关指标与可切除胃癌患者预后的相关性[J]. 实用肿瘤学杂志, 2021, 35(6): 517-522.
[8]	卢俊蓉, 王惠文, 何东风. SALL4高表达在食管鳞癌临床病理及预后判定中的意义[J]. 实用肿瘤学杂志, 2021, 35(5): 420-425.
[9]	余幼林, 余军林, 胡超华, 沈雄山, 李卫民, 卢婷, 杨峰, 杨青青, 刘程浩. 基于生物信息学方法分析LAYN在甲状腺癌中临床预后价值及对免疫细胞浸润的影响[J]. 实用肿瘤学杂志, 2021, 35(4): 357-364.
[10]	刘文, 乔文波. 程序性死亡蛋白1及其配体在结直肠癌中的临床研究现状[J]. 实用肿瘤学杂志, 2021, 35(4): 370-375.
[11]	董晓平, 张雪, 郭冬利, 贺宇彤. 肺鳞状细胞癌预后相关影响因素研究进展[J]. 实用肿瘤学杂志, 2021, 35(4): 380-385.
[12]	尹蕾, 杨旭东, 杨悦, 牛星鉴, 周晓平, 姬宏飞, 王一然. 中性粒细胞与淋巴细胞比值在非小细胞肺癌患者预后评估中的临床意义及相关机制研究[J]. 实用肿瘤学杂志, 2021, 35(2): 117-124.
[13]	秘嘉庆, 秦倩, 马惠涵, 马梅杰, 冯勤梅. TTK在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 188-192.
[14]	张璐,陆静钰(综述),陆海军(审校). 头颈部鳞癌相关生物标志物与免疫治疗预后的关系[J]. 实用肿瘤学杂志, 2021, 35(1): 55-58.
[15]	牛明, 于歌. 促进乳腺癌增殖转移和肿瘤干细胞特征的研究[J]. 实用肿瘤学杂志, 2020, 34(6): 518-523.

肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析

Analysis of the correlation between sarcopenia and the clinicopathological characteristics and prognosis of advanced NSCLC

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价